Introduction
is usually expressed on a logarithmic pH scale [1] . Complex solutes, including many biologically important molecules, are often ascribed with several K a values, reflecting distinct protonbinding sites. At a given pH, protonatable sites with very high or very low pK a will be almost completely titrated or unbound, respectively. By contrast, the concentration (in a macroscopic sense) of protonated and unprotonated sites will be balanced if pK a is near the ambient pH. Such molecules are of major biological importance for two reasons. Firstly, the availability of HA and A protects (buffers) solutions from large pH changes in response to acidbase challenges. Secondly, a sustained change in pH alters the H þ ions (a form of post-translational modification) [2] . It is therefore not surprising that only a narrow range of pH is compatible with eukaryotic function. Living tissue, unlike a simple salt solution, engages continually in the production or consumption of acids (or bases) through chemical reactions. Because of cellular respiration (yielding CO 2 and lactic acid), most cells are net acid-producers hence intracellular pH ( pH i ) has a tendency to fall. A sustained and substantial acid-base challenge cannot be corrected by pH buffers alone because of their finite capacity (i.e. buffering reduces the amplitude of pH-changes but cannot, on its own, eliminate or reverse these). Also in contrast to a simple solution, living tissue is compartmentalized into intra-and extracellular spaces separated by the cell membrane (figure 1). The ability of biological membranes to allow the passage of selected molecules can give rise to pH differences between the compartments. Selective transport of H þ -ions (or molecules that release or take-up H þ ions such as CO 2 or HCO 3 À : the so-called H þ -equivalents) across membranes is thus an effective means of changing pH i . As explained later, the usual pH iregulatory strategy of cells is to balance the internal production of acid (or base) with an equal 'corrective' efflux of acid (or base) across the cell membrane. The biological potency and chemical omnipresence of H þ ions highlight the importance of regulating pH (where pH is controlled to suit protein function) and of adapting biology to a particular pH level (where gene products are selected or changed on the basis of ambient pH). As will be explained below, these processes are believed to play an important role in cancer disease progression.
Low micro-environmental O 2 tension and pH as hallmarks of cancer
Histological studies in the 1950s by Thomlinson and Gray established that human tumours grow around blood vessels and that the outermost cells beyond a distance of approximately 200 mm from blood become necrotic [3] . The presence of areas with low (,1%) O 2 tension is associated with increased metastasis and poor patient survival [5] , giving rise to the notion that hypoxia is a hallmark of malignant cancer. The discovery that hypoxia alters cell biology [6] (e.g. via hypoxia-inducible factor HIF1a [7] ) offered a mechanism for adaptive changes, such as the switch-over to glycolytic metabolism (Warburg effect; [8] ). Tumour hypoxia has since become a topic of considerable research, achieving promising outcomes with respect to understanding aetiology, improving diagnosis and developing treatments [6, 9] . Among other micro-environmental factors specifically identified in tumours, extracellular acidity has emerged as another cancer hallmark [10] [11] [12] . Contrary to initial expectations, the intracellular compartment was shown to be alkaline [13] 
Production and venting of metabolic acids
Cancer cells require a substantial input of energy to support their intensive programme of growth. This explains the high glucose utilization rate, measured to be most typically in the range 0.1-1 mmol (g tissue) 21 min 21 [14] . Under aerobic conditions, respiration of glucose to CO 2 is coupled to the production of ATP, which consumes an H þ ion:
This acid-base disturbance is then cancelled out by ATP breakdown elsewhere in the cell. As a result, the source of acidity from aerobic metabolism is CO 2 , once it hydrates to H þ and HCO 3 À ions. Under anaerobic conditions, glycolytic ATP production is coupled to the chemical conversion of glucose to anionic lactate [15] :
This 
In some cells, such as erythrocytes [39] ) ions also alkalinizes the cell because the subsequent reaction with intracellular H þ ions produces CO 2 , the passive venting of which completes the acid-extrusion process. HCO 3 À transport is considered to be H þ -equivalent flux. [17] These findings highlight the importance of investigating pH i regulation in the context of the tumour milieu. In summary, the resting pH i of a cell can be defined as the steady-state point at which net metabolic acid production is balanced by net membrane H þ /H þ -equivalent transport.
These fluxes are likely to show considerable regional variation in solid tumours, resulting in the potential for large pH i gradients alongside pH e non-uniformity. This important aspect of tissue pH regulation cannot be investigated by measuring pH in suspensions or two-dimensional monolayers prepared from cultured cells. A more instructive approach to studying pH non-uniformity in tissue is to image cancer-derived multicellular three-dimensional spheroids for pH i and pH e (figure 5) [25, 36, 56] . in opposite directions. The magnitude of the pH e change will depend on extracellular buffering and H þ diffusion. In spheroids, which reproduce many aspects of the tissue microenvironment, the intrinsic extracellular buffering capacity is estimated to be equivalent to 5-10 mmol . (l interstitium) 21 .
(pH unit) 21 [21, 56] , i.e. lower than in the cytoplasm. As most fixed buffers reside on the surface of membranes, buffering capacity will depend on the degree of cell-cell packing (decreasing in 'looser' regions). Combined with weak diffusional coupling across the tumour interstitium, pH e changes may be considerable and add to the acidosis imposed by CO 2 and H þ -lactate venting (explaining why glycolysis-deficient tumours still generate low pH e [57, 58] ). Displacements of pH e can slow the transport cycle, either by means of trans inhibition or activation of allosteric sites [51, 55, 59] . For instance, acid extrusion by Na þ /H þ exchange is inhibited sharply at reduced pH e [60] . In multi-cellular spheroids, this inhibitory effect can be lessened by increasing extracellular mobile buffering capacity [56] . Since CO 2 /HCO 3 À is the principal extracellular mobile buffer, the activity of exofacial CAs can have a substantial impact on the feedback between pH e and pH i -regulating transporters. The sensitivity of at least some pH i regulators to cellular energetics and to pH e may protect cancer cells from ATP depletion and excessive extracellular acidification beyond a point that is more damaging than a partially regulated pH i . In a growing tumour, where diffusion distances and metabolic rate change continuously, these safety checks can be important for the process of somatic evolution which seeks the most viable phenotype.
pH sensing, pH-driven selection and clinical perspectives
Cancer cells must be able to detect and respond to microenvironmental factors so that these can then guide somatic evolution. In the case of hypoxia, HIF is a transducer between O 2 tension and cellular effects. The pH sensors involved in cancer disease progression have proved to be more challenging to identify, possibly because of difficulties in distinguishing bona fide pH sensors from the plethora of proteins that bind H þ ions [2] . Cells sensing an alkaline pH i have been shown to proliferate [61] , enter the cell cycle [62, 63] , differentiate [64] , migrate [65, 66] , reduce apoptosis [67] and clastogenesis [68] , and undergo malignant transformation [69, 70] -events that are critical in cancer formation and metastasis. Considering the complexity of these processes, the observed pH i sensitivity may involve a number of H þ -binding molecular switches. pH sensing is not confined to the cytoplasm: H þ sensing G-protein-coupled receptors [71] , H þ sensing ion channels (ASICs) [72] and the pH sensitivity of a number of ion channels [73] offer a means by which cells could respond to the pH of the tumour milieu. Among the titratable sites on proteins, the imidazole group of histidine is an attractive candidate for pH-sensing moieties [74] . Although histidine makes up less than 3% of most proteins, it is commonly found in active or binding sites [75] . The reason for this can be traced to imidazole's pK a of 6.5, which means that even small changes in pH i can greatly affect its ionization state and ability to make salt bridges with other amino acids or prosthetic groups. With its unique chemical properties, histidine does not substitute well with any other amino acid [75] . Considering its prominence in active/binding sites, histidine mutations are expected to alter protein function. Among the three most common missense mutations in the tumour suppressor protein p53, two involve substitutions to histidine (Arg 175 ! His, Arg 275 ! His) [76] . A well-described Arg 337 ! His mutation destabilizes p53 tetramerization and hinders its interaction with DNA because a critical salt bridge with Asp 352 is no longer stable at normal pH i [77] .
Over the long course of cancer disease progression, cells accumulate genetic changes that are retained if selected positively by the micro-environment [78] [79] [80] . If extracellular acidity (a complex derivative of diffusion distance, buffering, metabolic rate and membrane transport) were a major selection pressure (as hinted by its prominence as a cancer hallmark) then at least some mutations are likely to relate to genes or gene regulators for H þ /H þ -equivalent transporters, pH sensors or proteins involved in acid-yielding metabolic pathways [79] . Poor prognosis for tumours with low pH e may indicate that acidity has identified a population of cells with the appropriate pH sensing and regulatory apparatus necessary to thrive and even become resistant to drugs (e.g. weakly basic drugs such as doxorubicin [81, 82] ). As cancer cells (and possibly stromal cells [83] ) have ultimate control over pH e , the direction and rate of change of this selection pressure can be adapted to optimise disease progression. The higher acid-per-ATP yield of glycolysis, when compared with mitochondrial respiration, may explain the prominence of the Warburg effect in cancer [84] . In summary, the plasticity of pH i regulation and versatility of protein pH sensitivity offer a mechanism for cancer cells to exploit pH as a selection pressure. By contrast, the genetic stability of normal host cells would hinder their adaptability to the micro-environment. Growing evidence for the importance of pH in cancer biology has solicited many ambitious ideas for therapy targeting pH-handling proteins with low molecular weight inhibitors or monoclonal antibodies [85] [86] [87] . The strategy of blocking acid extrusion from cancer cells and allowing intracellular acid to accumulate to lethal levels may be achieved readily in vitro, but efficacy in vivo would need to overcome major obstacles. Firstly, acid-base handling proteins are also important for normal cells and inhibition could lead to unacceptable systemic toxicity. It is therefore essential to identify, at the molecular level, acid-base handling mechanisms in cancer that differ substantially from normal cells. For instance, hypoxia-induced MCT4 and CAIX are associated with tumours. Alternatively, drugs could be tailored chemically to become more efficacious in the tumour milieu, e.g. through chemical activation at low pH and/or O 2 tension. A second obstacle is the redundancy in mechanisms for acid extrusion that could compensate for the targeted protein, particularly in cancer cells which have the means to change and adapt dynamically. This raises the question of whether therapy targeted at manipulating pH i will have the desired clinical efficacy. The hypothesis of acid-driven disease progression has highlighted the importance of extracellular pH as a target for therapy. Unlike interventions that alter intracellular pH by targeting one (or more) of many membrane-bound transporter proteins, extracellular pH could be manipulated by altering H þ diffusivity or buffering capacity. Raising mobile buffering capacity with systemic bicarbonate offers an attractive means of changing the course of acid-driven somatic evolution by ablating the underlying selection pressure [88] . The steady flow of new data in support for the prominent role played by H þ ions in cancer will keep pH in the spotlight for novel therapeutic approaches for years to come.
Concluding remarks
Tissues can regulate and adapt to a particular pH distribution through a two-way interaction between pH and proteins. By continuously evolving superior phenotypes, cancer cells can exploit this interaction to out-compete host cells and metastasize. As the common denominator of a vast array of chemical reactions and transport processes, it is challenging to understand how the concentration of H þ ions is regulated and sensed. However, the combination of physiological, biochemical, genetic and computational approaches is supplying new ideas on how to exploit the pH/biology interaction in the management of cancer.
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